Clover_Logo_Green_RGB.jpg
Clover Health Launches New Clinical Program Targeting Chronic Kidney Disease in Partnership with Cricket Health
December 09, 2021 09:00 ET | Clover Health Investments, Corp.
The Clover Assistant synthesizes health data and surfaces personalized clinical recommendations to physicians to drive earlier disease detection and interventionSpecialty kidney services now...
TIP_link_300x300.jpg
Hematuria Treatment Market Size ($1,103.61Mn by 2028) Led by Urinary Tract Infections (17.31% Market Share in 2020) Impact of Coronavirus Outbreak and Global Analysis & Forecast by TheInsightPartners.com
October 29, 2021 13:45 ET | The Insight Partners
New York, Oct. 29, 2021 (GLOBE NEWSWIRE) -- Hematuria Treatment Market: Key InsightsAccording to our new research study on Hematuria Treatment Market Size and Forecast to 2028 - COVID-19 Impact and...
22157.jpg
Global Renal Care Management Market Research Report 2021: Value-based Renal Care to Provide a Strong Platform for Payer-driven Innovations and Major Industry Disruptions
September 29, 2021 07:13 ET | Research and Markets
Dublin, Sept. 29, 2021 (GLOBE NEWSWIRE) -- The "Global Renal Care Management Growth Opportunities" report has been added to ResearchAndMarkets.com's offering. The global prevalence of CKD is...
July 30, 2021 - ROSEN LOGO.jpg
ARDX FINAL DEADLINE TUESDAY: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Ardelyx, Inc. Investors with Losses to Secure Counsel Before Important September 28 Deadline in Securities Class Action – ARDX
September 26, 2021 15:15 ET | The Rosen Law Firm PA
NEW YORK, Sept. 26, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Ardelyx, Inc. (NASDAQ: ARDX) between August 6, 2020 and...
July 30, 2021 - ROSEN LOGO.jpg
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Ardelyx, Inc. Investors with Losses to Secure Counsel Before Important September 28 Deadline in Securities Class Action – ARDX
September 17, 2021 19:15 ET | The Rosen Law Firm PA
NEW YORK, Sept. 17, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Ardelyx, Inc. (NASDAQ: ARDX) between August 6, 2020 and...
July 30, 2021 - ROSEN LOGO.jpg
ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages Ardelyx, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ARDX
August 27, 2021 17:45 ET | The Rosen Law Firm PA
NEW YORK, Aug. 27, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Ardelyx, Inc. (NASDAQ: ARDX) between August 6, 2020 and...
July 30, 2021 - ROSEN LOGO.jpg
ARDX INVESTOR NOTICE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Ardelyx, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ARDX
August 19, 2021 16:15 ET | The Rosen Law Firm PA
NEW YORK, Aug. 19, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Ardelyx, Inc. (NASDAQ: ARDX) between August 6, 2020 and...
July 30, 2021 - ROSEN LOGO.jpg
ARDX INVESTOR NEWS: ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages Ardelyx, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – ARDX
August 13, 2021 18:15 ET | The Rosen Law Firm PA
NEW YORK, Aug. 13, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Ardelyx, Inc. (NASDAQ: ARDX) between August 6, 2020 and...
July 30, 2021 - ROSEN LOGO.jpg
ROSEN, A RESPECTED AND LEADING LAW FIRM, Encourages Ardelyx, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline – ARDX
August 03, 2021 15:45 ET | The Rosen Law Firm PA
NEW YORK, Aug. 03, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of...
KBP Logo.png
KBP Biosciences Announces A Greater Than 10 mm Hg Systolic Blood Pressure Reduction in The BLOCK-CKD Phase 2b Study of KBP-5074 in Advanced Chronic Kidney Disease Patients with Uncontrolled Hypertension as Published in Hypertension
June 16, 2021 08:00 ET | KBP BioSciences
KBP-5074, a highly-selective non-steroidal mineralocorticoid receptor antagonist, lowered clinic systolic blood pressure (SBP) by 10.2 mm Hg with reduced hyperkalemia risk in the phase 2b studyArticle...